Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NUC 7738

Next Previous
Drug Profile

NUC 7738

Alternative Names: NUC 7738

Latest Information Update: 18 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cardiff University
  • Developer NuCana; University of St Andrews
  • Class Antineoplastics; Nucleosides
  • Mechanism of Action RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Lymphoma; Solid tumours
  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 16 Oct 2023 Efficacy data from a phase-II clinical trials in Solid tumours released by NuCana
  • 11 Oct 2023 Updated adverse events data from a phase I/II trial in Solid tumours and Lymphoma presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2023)
  • 12 Sep 2022 Efficacy and adverse events data from a phase I/II trial in Solid tumours presented in an oral presentation at the European Society of Medical Oncology (ESMO-2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top